- Home
- FOR vs URGN Comparison
FOR vs URGN Comparison
Compare FOR & URGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FOR
- URGN
- Stock Information
- Founded
- FOR 2005
- URGN 2004
- Country
- FOR United States
- URGN United States
- Employees
- FOR N/A
- URGN N/A
- Industry
- FOR Real Estate
- URGN Biotechnology: Pharmaceutical Preparations
- Sector
- FOR Finance
- URGN Health Care
- Exchange
- FOR Nasdaq
- URGN Nasdaq
- Market Cap
- FOR 1.2B
- URGN 1.1B
- IPO Year
- FOR 2007
- URGN 2017
- Fundamental
- Price
- FOR $24.54
- URGN $25.90
- Analyst Decision
- FOR Strong Buy
- URGN Strong Buy
- Analyst Count
- FOR 4
- URGN 8
- Target Price
- FOR $31.25
- URGN $28.50
- AVG Volume (30 Days)
- FOR 128.6K
- URGN 1.4M
- Earning Date
- FOR 10-28-2025
- URGN 11-06-2025
- Dividend Yield
- FOR N/A
- URGN N/A
- EPS Growth
- FOR N/A
- URGN N/A
- EPS
- FOR 3.29
- URGN N/A
- Revenue
- FOR $1,662,400,000.00
- URGN $96,516,000.00
- Revenue This Year
- FOR $1.24
- URGN $35.07
- Revenue Next Year
- FOR $8.97
- URGN $117.83
- P/E Ratio
- FOR $7.47
- URGN N/A
- Revenue Growth
- FOR 10.14
- URGN 8.00
- 52 Week Low
- FOR $18.00
- URGN $3.42
- 52 Week High
- FOR $31.19
- URGN $26.28
- Technical
- Relative Strength Index (RSI)
- FOR 47.78
- URGN 70.17
- Support Level
- FOR $22.81
- URGN $22.70
- Resistance Level
- FOR $25.34
- URGN $26.28
- Average True Range (ATR)
- FOR 0.79
- URGN 1.88
- MACD
- FOR -0.07
- URGN 0.22
- Stochastic Oscillator
- FOR 66.79
- URGN 95.45
About FOR Forestar Group Inc
Forestar Group Inc is a residential lot development company with operations across the United States. The core business segment for the company is real estate which generates all of it's revenues. The firm fundamentally acquires entitled real estate and develops it into finished residential lots for sale to homebuilders with a strategic focus on asset turns and efficiency. Single-family residential communities account for the majority of their real estate projects. The company utilizes a lower-risk business model mainly by investing in short duration, phased development projects.
About URGN UroGen Pharma Ltd.
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. Their flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with investigational candidate UGN-102 (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. Additionally, their immuno-uro-oncology pipeline includes UGN-301 (zalifrelimab), an anti-CTLA-4 antibody, intended for both monotherapy and combination therapy. Revenue is generated from product sales.